Odimma develops a personalized immunotherapy platform that utilizes artificial intelligence and synthetic DNA technology to create targeted treatments based on the unique genetic markers of individual tumors. This approach enables a robust immune response against specific cancer types, including melanoma, colorectal, and breast cancer, addressing the challenge of tumor heterogeneity in cancer therapy.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail due to the unique genetic makeup of individual tumors and the resulting heterogeneity in tumor markers. This variability makes it difficult to develop therapies that effectively target all cancer cells within a patient.
Solution
Odimma is developing a personalized immunotherapy platform that leverages artificial intelligence and synthetic DNA technology to create targeted treatments based on the unique genetic markers of individual tumors. The platform aims to induce a robust cellular immune response against specific tumor markers, leading to a strong anti-tumor effect. By harnessing the patient's own immune system to recognize these markers, Odimma's approach seeks to improve outcomes for hard-to-treat cancers.
Target Audience
The primary target audience includes cancer patients with solid tumors, oncologists, and researchers in the field of immuno-oncology.
Features
- AI-driven identification of unique tumor markers for personalized treatment design
- Synthetic DNA technology for creating targeted immunotherapies
- Platform designed to induce a strong cellular immune response
- Demonstrated anti-tumor effects in preclinical models of melanoma, colorectal, and breast cancer